Keywords: Biogen Idec, Swedish Orphan Biovitrumm Hemophilia B, rFIXFc, BLA submission

Positive Ph III results for Biogen Idec and SOBI's hemophilia B agent

Article | 27 September 2012

Print This

US biotech firm Biogen Idec (Nasdaq: BIIB) and partner Swedish Orphan Biovitrum (STO: SOBI) have announced positive results from B-LONG, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in